Trials
4 active
19 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administered once daily, preferably in the morning, with food”In the company’s words, NCT05535946 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis (2 trials), Moderately to Severely Active Crohn Disease
- Main trialPhase 3
- “This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This…”In the company’s words, NCT05535946 on ClinicalTrials.gov
- Other names
- ABX464
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJanssen Research & Development, LLC · Phase 3
- IcotrokinraJanssen Research & Development, LLC · Phase 3
- TirzepatideEli Lilly · Phase 3
Coming up3
- DecPhase 2 trial completes · ClinicalTrials.gov
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovCompletion date moved: 2026-09 to 2027-04 · ClinicalTrials.gov NCT07453784
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 28 Apr 2026 | ABTECT - Maintenance | |
| Phase 2Recruiting | Dec 2026 | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | |
| Phase 2Active, not recruiting | Mar 2028 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | |
| Phase 1Recruiting | Apr 2027 | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | |
| Phase 3Completed | 24 Jun 2025 | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 | |
| Phase 3Completed | 24 Jun 2025 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | |
| Phase 2/3Terminated | 5 Mar 2021 | ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 | |
| Phase 2/3Withdrawn | 19 Sep 2022 | Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients | |
| Phase 2Completed | 30 Aug 2017 | ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment | |
| Phase 2Completed | 25 Jul 2018 | ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | |
| Phase 2Completed | 1 Apr 2021 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis | |
| Phase 2Completed | 27 Apr 2021 | Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis | |
| Phase 2Completed | 12 Jul 2022 | Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis | |
| Phase 2Completed | 23 Jan 2023 | Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis | |
| Phase 2Completed | 23 Feb 2023 | Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis | |
| Phase 1/2Completed | 27 Dec 2018 | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults | |
| Phase 1Completed | Jul 2014 | ABX464 First in Man Study | |
| Phase 1Completed | 18 May 2021 | Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 | |
| Phase 1Completed | 18 Feb 2022 | Safety and Pharmacokinetics Study in Healthy Japanese Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026